To better explore the prognostic value of CD4+TIL and CD8+TIL in patients with NCT‐NSCLC, the CD4+/CD8+TIL ratio and change in CD4+TIL and CD8+TIL levels were analyzed using Kaplan–Meier survival analysis. The gene discussed is CD4; the disease is non-small cell lung carcinoma.